Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design

Nat Rev Immunol. 2010 Jul;10(7):527-35. doi: 10.1038/nri2801.

Abstract

One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine development has focused on inducing immunity to conserved regions of the HIV-1 envelope. However, new studies of the sequence-variable regions of the HIV-1 gp120 envelope glycoprotein have shown that there are conserved immunological and structural features in these regions. Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • AIDS Vaccines / chemistry
  • AIDS Vaccines / genetics*
  • AIDS Vaccines / immunology*
  • Amino Acid Sequence
  • Antibodies, Monoclonal / biosynthesis
  • Antibodies, Neutralizing / biosynthesis
  • Antigenic Variation
  • Conserved Sequence
  • Crystallography, X-Ray
  • Epitopes / chemistry
  • HIV Antibodies / biosynthesis
  • HIV Envelope Protein gp120 / chemistry
  • HIV Envelope Protein gp120 / genetics*
  • HIV Envelope Protein gp120 / immunology*
  • HIV Infections / immunology*
  • HIV Infections / prevention & control*
  • HIV-1 / chemistry
  • HIV-1 / genetics*
  • HIV-1 / immunology*
  • Humans
  • Models, Molecular
  • Molecular Sequence Data
  • Structure-Activity Relationship

Substances

  • AIDS Vaccines
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Epitopes
  • HIV Antibodies
  • HIV Envelope Protein gp120
  • gp120 protein, Human immunodeficiency virus 1